Purposes This study aims to ascertain the prevalence of cavitations in pulmonary metastases among pediatric and young adult patients with sarcoma undergoing tyrosine kinase inhibitor (TKI) therapy, and assess whether cavitation can predict clinical response and survival outcomes. Methods In a single‐...
discontinuation of multi-kinase inhibitor (MKIs), imatinib therapy due to TKI-associated adverse effects.10Toxicity can be attributed to bothon-targeteffects through excessive inhibition of the intended TK function; and/oroff-targeteffects resulting from the simultaneous inhibition of multiple other kinas...
First- generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience. Cancer Commun (Lond). 2018;38(1):51.Xiangyang,Yu,Xuewen,etc.First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients ...
In general, resistance mutations may overlap and vary between TKIs, which may be related to the types of the kinase. Therefore, if a resistance mutation occurs during TKI therapy, changing the TKI may be helpful. However, it is not a long-term solution. Cancer cells gradually develop resistan...
TYROSINE KINASE INHIBITOR (TKI) THERAPY IN COMPANION ANIMALS: YEAR ONE 来自 掌桥科研 喜欢 0 阅读量: 1 作者: C London 摘要: Inhibitors of tyrosine kinases (TKIs) have become an integral part of human cancer therapy over the past 5-10 years. Drugs such as Gleevec, Sutent, Sorafenib, ...
TKI: Tyrosine Kinase Inhibitor TNF: Tumor necrosis factor wt: Wildtype OH, designed research, performed experiments, analyzed the data, and wrote the paper. MKK and MB performed experiments, analyzed the data, and critically revised the manuscript. IGC analyzed the data. IA, FB, TL, TB, SK...
The tyrosine kinase inhibitor (TKI) Sunitinib is one the therapies approved for advanced renal cell carcinoma. Here, we undertake proteogenomic profiling of 115 tumors from patients with clear cell renal cell carcinoma (ccRCC) undergoing Sunitinib treatment and reveal the molecular basis of differential...
Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy.Blood.2017;129(1):38-47.doi: 10.1182/blood-2016-04-708560. 5. Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic ...
The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo(P) in Combination with Daunorubicin(D)/Cytarabine(C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-...
The second promising tyrosine kinase inhibitor against MTC,motesanib diphosphate(AMG-706), is a multikinase inhibitor targeting VEGF, platelet-derived growth factor, and Kit receptors, which lead toantiangiogenicand directantitumor activity. In a phase I trial with AMG-706, one patient with MTC exhi...